• Clearwater Paper Corporation v. Graphic Packaging International LLCAll claims unpatentable
  PTAB · Sep 23, 2026 · IPR2025-00878 · APJ Carl M Defranco · IPR · Final written decision

  Claims 1–3 and 11 are unpatentable as anticipated by Cleveland and obvious over Nakagawa and over Nakagawa combined with Tanner.

  RulingsFinal written decision

  • Skill levelSkill level petitioner adoptedDecided for petitioner

    “would have at least a bachelor’s degree in mechanical or chemical engineering, materials science, polymer science, or equivalent coursework, at least a year of experience developing paper-based laminates involving the application of polymer coatings to a substrate, and the appropriate industry familiarity with biodegradability standards and degradability techniques [and] . . . [l]ess work experience may be compensated by a higher level of education, such as a master’s degree, and vice versa. Pet. 16 (citing Ex. 1003 ¶ 50). Clearwater’s definition is uncontested, and we apply that definition here, as it accords with the level of skill reflected in the asserted prior art and the problems addressed in the specification of the ’126 patent. C. Claim Construction” slip op. at 6

  • Expert testimonyPetitioner expert creditedDecided for petitioner

    “We have reviewed the cited testimony of Clearwater’s expert, including their calculations for arriving at a coat weight in Nakagawa that falls within the claimed range. See Ex. 1003 ¶¶ 132–33. We find that testimony, which is unrebutted, both credible and supported by the evidence of record. Thus, in light of Clearwater’s contentions, the cited portions of Nakagawa, and the unrebutted testimony of Clearwater’s expert, we are persuaded that Nakagawa discloses or otherwise suggests each and every element of claim 1. See Pet. 45–54, 60–64. Clearwater also persuades us that Cleveland discloses the additional subject matter of dependent claims 2, 3, and 11. See Pet. 64–66. Thus, we determine that Clearwater demonstrates that claims 1–3 and 11 are unpatentable as obvious over Nakagawa. F. Ground 3—Obviousness Over Nakagawa and Tanner” slip op. at 17

  • Novelty / Anticipation (§102) › Prior-art status of a reference › Patents / published applications (effective date, provisional support)Reference is prior artDecided for petitioner

    “qualifies as prior art under 35 U.S.C. § 102(e)(1) “based on both its provisional and non-provisional filing dates.” Inst. Dec. 4 n.5. We were persuaded by Clearwater’s proof that Cleveland’s provisional (Ex. 1006) is “virtually identical” to Cleveland itself (Ex. 1005) and that the provisional provides written description support for at least claim 1 of Cleveland. See Pet. 18–21 (citing Ex. 1006, 2–6, 9). We were also persuaded by Clearwater’s showing that the provisional provides written support for the subject matter relied upon in Cleveland. Id. at 21–40 (citing Ex. 1006, 1–9). We are still persuaded by Clearwater’s showing. Thus, we see no reason to disturb our earlier finding that Cleveland is prior art to the ’126 patent.” slip op. at 7

  • Novelty / Anticipation (§102) › Anticipation standard (single reference, every element)UnpatentableUnpatentable

    “protectant layers has “a coat weight of from 5 to 30 lbs/3000 ft2.” As noted by Clearwater, Cleveland discloses a total coat weight for layers 14 and 16 as falling within the claimed range. Pet. 32–34 (citing Ex. 1005 ¶ 32). In particular, Cleveland discloses that “the coextruded layer of copolyester (irrespective of which side of the substrate the layer is disposed) is of a total coat weight of between about 10 and about 40 lb/3000 ft2 in any combination of between about 80/20 to 20/80 parts by weight of Ecoflex to Biomax,” of which “a total coat weight of 25 lb/3000 ft2 is preferred.” Ex. 1005 ¶ 32. As disclosed, Cleveland’s total coat weight range of 10–40 lb/3000 ft2 falls almost entirely within the claimed range, and the preferred total coat weight of 25 lb/3000 ft2 falls squarely within the claimed range. Thus, Cleveland satisfies claim elements [1.3.2] and [1.5.2]. See Titanium Metals Corp. v. Banner, 778 F.2d 775, 782 (Fed. Cir. 1985) (“[W]hen, as by a recitation of ranges or otherwise, a claim covers several compositions, the claim is anticipated if one of them is in the prior art.”) (citation omitted). As such, we find that Clearwater adequately demonstrates that Cleveland discloses all the elements of claim 1. 4. Dependent Claims” slip op. at 12

  Patent outcomesUS 8,637,126 unpatentable
  § 102 anticipation§ 103 obviousnesscites Phillips
  Patents in suitUS 8,637,126
• Charles River Laboratories, Inc. v. Seikagaku CorporationAll claims unpatentable
  PTAB · Sep 8, 2026 · PGR2025-00023 · APJ Per Curiam · PGR · Final written decision

  Claims 1–9 are unpatentable as anticipated by the ’629 publication; the claims are not entitled to the 2013 priority date.

  RulingsFinal written decision

  • Skill levelSkill level board ownOther

    “We find that a rigid requirement as to the subject of a POSITA’s doctoral degree (e.g., biochemical engineering, enzymology), or experience working specifically with horseshoe crab proteins, is not consistent with the evidence of record. See, e.g., Ex. 1067, 20:23–21:2 (Dr. Schaefer testifying that the fact the “name of [his] Ph.D. is immunology . . . does not change the fact that the core of [his] thesis training was really in molecular biology”), 22:3–15 (explaining that “the fact that the production of proteins recombinantly is mostly species agnostic”); Ex. 1069, 45:20–47:17 (Dr. Morris testifying that whether a person is a POSITA depends on the person’s “experience, [ ] publications,” and work done for the Ph.D. rather than the name of the Ph.D. program). We also find that evidence of record supports Petitioner’s assertion that, for purposes of defining a POSITA, “[m]ore education could substitute for experience, and vice versa.” See, e.g., Pet. 22; Ex. 1065, 99:14–100:3. Accordingly, based on the entirety of the trial record, we find a POSITA with respect to the claims of the ’109 patent would have had a two years of experience with cloning genes, expressing cloned genes as proteins, and/or characterizing such cloned genes and proteins, with more education being able to substitute for experience, and vice versa. A POSITA may also have collaborated with others, including those with specific experience in utilizing or assessing horseshoe crab Factor C for endotoxin detection and quantitation.” slip op. at 9

  • Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)No construction neededOther

    “Neither party proposes an express construction of any claim term. See Pet. 22–23 (not proposing any constructions); PO Resp. 23 (“Patent Owner agrees that the terms can be afforded their plain and ordinary meaning.”). However, Patent Owner states that some of Petitioner’s arguments implicitly construe claim 1 in an erroneous manner. PO Resp. 23–28. “For example, Petitioner argues that ‘an adequate written description would have to either disclose representative examples of the possible working cascades of various proteins or some accurate structural feature of the claimed proteins that allow them to function in the claimed assay as a whole.’” Id. at 23 (quoting Pet. 35). Patent Owner argues that, contrary to what Petitioner’s argument allegedly implies, “Claim 1 is directed to a method for producing an endotoxin assay agent” and does not require the use – Owner that claim 1 does not require the use of endotoxin assay agent. However, the claimed endotoxin assay agent must be capable of performing the assay, as counsel for Patent Owner acknowledged. Tr. 83:5–9.” slip op. at 10

  • BurdenNot shown unpatentable

    “In this case, to show that the claims of the ’109 patent are unpatentable for lack of written description, Petitioner would have needed to show that the specification as filed (i.e., the ’420 application) fails to reasonably convey to those skilled in the art that Patent Owner had possession of the claimed subject matter as of the July 3, 2023, filing date. Petitioner did not. Pet. 23–24. Nor does Petitioner’s declarant offer testimony that could support such a showing. See Ex. 1003 ¶50 (“I have been asked to provide my opinions as to the state of the art in this field for purposes of determining what the inventors disclosed as their invention as of December 10, 2013.”), ¶51 (“Whenever I offer an opinion in this declaration about the knowledge of a POSA, the manner in which a POSA would have understood the claims of the ’109 patent or its description, the manner in have been led to do based on the prior art, I am referencing the December 10, 2013 timeframe.”). In our Institution Decision, we stated: Although the ’420 application is essentially identical to the ’767 application, the person of ordinary skill in 2013 is not the same as in 2023. See Ariad, 598 F.3d at 1351 (“[T]he [written description] test requires an objective inquiry into the four corners of the specification from the perspective of a person of ordinary skill in the art.” (emphasis added)). Thus, the information presented in the Petition, which is limited to the perspective of a 2013 POSITA, does not demonstrate that it is more likely than not that at least 1 of the claims challenged in the Petition is unpatentable for lack of written description. Inst. Dec. 12 (alterations in original). During trial, Petitioner did not present any further arguments in support of Ground 1. See generally Pet. Reply. Petitioner has failed to prove that claims 1–9 are unpatentable for failing to meet the written description requirement set forth in 35 U.S.C. § 112(a).” slip op. at 12

  • Disclosure Requirements (§112) › Written description (Ariad)Written description inadequateNot shown unpatentable

    “Although the evidence before us shows that, in 2013, a POSITA knew how to recombinantly express genes in expression systems such as CHO or HEK-293 cell lines, the evidence shows that this was true only for genes whose genetic sequences were known or readily available. See, e.g., Ex. 1069, 34:11–22 (“Q. Okay. So you would agree that the creation of the recombinant protein requires the underlying sequence of, as you said, the original animal? A. Of course.”) Because it is undisputed that, in 2013, the genetic sequence for Limulus polyphemus Factor C was unknown, or least not publicly available, Falko-Gunter does not support a finding of adequate written description here. See, e.g., Tr. 48:18–19 (“Patent Owner agrees that there had not been, as of 2013, the full length cDNA sequence for Limulus polyphemus Factor C published.”).” slip op. at 23

  Patent outcomesUS 11,959,109 unpatentable
  Claim construction§ 102 anticipation§ 112 disclosure
  Patents in suitUS 11,959,109
• Charles River Laboratories, Inc. v. Seikagaku CorporationAll claims unpatentable
  PTAB · Sep 8, 2026 · IPR2025-00440 · APJ Tawen Chang · IPR · Final written decision

  Claim 21 is unpatentable as obvious over Mizumura with either the ’498 PCT or McClymont; the Revised Contingent Motion to Amend proposing claim 22 is denied.

  RulingsFinal written decision

  • Skill levelSkill level patent owner adoptedDecided for patent owner

    “overlap to a significant degree, i.e., a person with a Ph.D. in a discipline related to biological sciences and having had at least two years of work experience. However, the parties’ proposals differ slightly in the specific subjects in which a POSA would have had a doctoral degree, and whether the person’s work experience must have been directly related to horseshoe crab Factor C. As an initial matter, we find that a rigid requirement as to the subject of a POSA’s doctoral degree (e.g., biochemical engineering, enzymology), or experience working specifically with horseshoe crab proteins, is not consistent with the evidence of record. See, e.g., Ex. 1067, 20:23–21:2 (Dr. Schaefer testifying that the fact the “name of [his] Ph.D. is immunology . . . does not change the fact that the core of [his] thesis training was really in molecular biology”), 22:3–15 (explaining “the fact that the production of proteins recombinantly is mostly species agnostic”); Ex. 1069, 45:20–47:17 (Dr. Morris testifying that whether a person is a POSA depends on the person’s “experience, [ ] publications,” and work done for the Ph.D. rather than the name of the Ph.D. program). We also find that evidence of record supports Petitioner’s assertion that, for purposes of defining a POSA, “[m]ore education could substitute for experience, and vice versa.” See, e.g., Pet. 19; Ex. 1065, 99:14–100:3. with respect to the claims of the ’318 patent would have had a Ph.D. in molecular biology, biochemistry, or a related discipline, and about two years of experience with cloning genes, expressing cloned genes as proteins, and/or characterizing such cloned genes and proteins, with more education being able to substitute for experience, and vice versa. A POSA may also have collaborated with others, including those with specific experience in utilizing or assessing horseshoe crab Factor C for endotoxin detection and quantitation.” slip op. at 13

  • Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)No construction neededOther

    “C. Claim Construction The parties agree that “the terms in claim 21 can be afforded their plain and ordinary meaning for purposes of this proceeding” without further construction. Pet. 19–20; PO Resp. 11. Because express claim construction is not needed to resolve the issues in this case, we need not, and do not, construe expressly any claim term for purposes of this Decision. See Realtime Data, LLC v. Iancu, 912 F.3d 1368, 1375 (Fed. Cir. 2019) (“The Board is required to construe ‘only those terms . . . that are in controversy, and only to the extent necessary to resolve the controversy.’”) (quoting Vivid Techs., Inc. v. Am. Sci. & Eng’g, Inc., 200 F.3d 795, 803 (Fed. Cir. 1999)).” slip op. at 14

  • Disclosure Requirements (§112) › Written description (Ariad)Written description inadequateNot entitled to earlier dateDecided for petitioner

    “Carrying Out the Invention section, that “[t]he Factor C of the present invention is a Factor C derived from a horseshoe crab,” and states later in the same section that “[e]xamples of the horseshoe crab include . . . Limulus polyphemus.” Ex. 1006, 40. However, none of the remaining portions of ’767 application cited by Patent Owner relate directly to L. polyphemus; instead, the remaining portions of ’767 application cited by Patent Owner are directed to other species, in particular the Japanese horseshoe crab T. tridentatus. Further, Patent Owner’s witness, Dr. Schaefer, conceded that the ’767 application does not contain Factor C sequence information for L. polyphemus. See, e.g., Ex. 1067, 44:25–45:23. Although “[n]o length requirement exists for a disclosure to adequately describe an invention,” Falko-Gunter, 448 F.3d at 1365–1366, we are persuaded that a POSA would not, based on the totality of the above disclosures, reasonably understand that the inventors were in possession of the claimed HEK-293 recombinant L. polyphemus Factor C protein, in view of the state of the art as of December 10, 2013. In this regard, we note that adequate written description of a biological molecule, such as a HEK293 recombinant L. polyphemus Factor C protein, requires “more than a mere statement that it is part of the invention and reference to a potential method for isolating it”; instead, what is required is “‘a precise definition, such as by structure, formula, chemical name, or physical properties,’ not a mere wish or plan for obtaining the claimed chemical invention.” The Regents of the” slip op. at 21

  • Obviousness (§103) › Motivation to combine / reasonable expectation of successMotivation foundReasonable expectation foundDecided for petitioner

    “Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348, 1364 (Fed. Cir. 2007). Neither do we see Petitioner’s arguments regarding the December 10, 2013 priority date to be “mutually opposed” as Dr. Schaefer testified. Ex. 1067, 216:4– 24. Instead, we credit evidence of record, including Dr. Jain’s testimony and the February 22, 2018 Mizumura Declaration, that existence of the full sequence would permit a more complete analysis and that such an analysis would provide a POSA with a reasonable expectation that the claimed L. polyphemus recombinant protein would have a residual activity within the claimed range. See, e.g., Ex. 1029, 2–5; Ex. 1010, 48; Ex. 1065, 117:14– 130:24 (explaining that comparison of partial sequences in the Tokunaga 1991 publication showed “difference around the cleavage site” between T. tridentatus and L. polyphemus but comparison of the full sequence revealed that “the catalytic triad of histidine, serine, aspartate . . . to be more similar between Tachypleus and Limulus”). Patent Owner asserts that “Petitioner’s reliance on a statement made by Dr. Mizumura in a declaration submitted during prosecution of the ’767 Application fails to fill the gap in the analysis” regarding reasonable expectation of success, because the declaration “offers no evidence of the percentage of conserved amino acid substitutions that exist to support the conclusion that a POSA would have expected residual activity to be maintained between Tachypleus tridentatus and Limulus polyphemus” PO Resp. 47. However, as noted above, Dr. Mizumura provides an alignment of Factor C proteins from the two different species of horseshoe crab, determines that the similarity between the amino acid sequence is 99.5%, states that the amino acid residues that can undergo N-type sugar chain that L. polyphemus, like T. tridentatus, would also be less susceptible to inhibition by ions. Ex. 1029, 4–5. For the reasons discussed above, we also disagree with Patent Owner’s assertion that Petitioner’s reasonable expectation of success argument is “nothing more than conclusory assertions with no support.” PO Resp. 46. Rather, we find Petitioner has shown, by a preponderance of the evidence, that a POSA would have had reason to combine the teachings of Mizumura and the ’498 PCT, with a reasonable expectation of success in arriving at the Factor C protein recited in claim 21.” slip op. at 38

  Patent outcomesUS 11,236,318 unpatentable
  Claim construction§ 103 obviousness§ 112 disclosurecites KSR · Graham
  Patents in suitUS 11,236,318
• Merck Sharp & Dohme LLC v. Halozyme, Inc.All claims unpatentable
  PTAB · Sep 1, 2026 · PGR2025-00017 · APJ Jeffrey N Fredman · PGR · Final written decision

  Claims 1, 2, 6–15, and 17–30 are unpatentable because the challenged claims lack written-description support and are not enabled.

  RulingsFinal written decision

  • Skill levelSkill level petitioner adoptedDecided for petitioner

    “II. ANALYSIS A. Level of Ordinary Skill in the Art We consider the grounds of unpatentability in view of the” slip op. at 9

  • Expert testimonyPetitioner expert creditedPatent owner expert discountedDecided for petitioner

    “been able to use the data in the Specification to make reasonable predictions about the effect of multiple modifications on hyaluronidase activity, we view this testimony to at most describe a research plan (i.e., a “tool to engage in further modification”14) for finding the recited polypeptides rather than demonstrating the inventors were in possession of the full scope claimed. This is particularly so given the limits of the then-available analytical tools noted above and the fact that the structural connections and three dimensional modeling Patent Owner’s experts attempt to make (see, e.g., Ex. 2070 ¶¶ 129–213; Ex. 2068 ¶¶ 123–125) do not appear in the written description itself. To the extent the experts disagree on this point, we credit the testimony of Petitioner’s experts over that of Patent Owner’s. See Ex. 1133 ¶¶ 111–230 (identifying problems with the approaches proposed by Patent Owner’s experts). For these reasons, we find that a preponderance of the evidence of record better supports a finding that in the 2011–2012 timeframe, it would have been unpredictable to identify which multiple” slip op. at 53

  • Disclosure Requirements (§112) › Written description (Ariad)Written description inadequateUnpatentable

    “been able to use the data in the Specification to make reasonable predictions about the effect of multiple modifications on hyaluronidase activity, we view this testimony to at most describe a research plan (i.e., a “tool to engage in further modification”14) for finding the recited polypeptides rather than demonstrating the inventors were in possession of the full scope claimed. This is particularly so given the limits of the then-available analytical tools noted above and the fact that the structural connections and three dimensional modeling Patent Owner’s experts attempt to make (see, e.g., Ex. 2070 ¶¶ 129–213; Ex. 2068 ¶¶ 123–125) do not appear in the written description itself. To the extent the experts disagree on this point, we credit the testimony of Petitioner’s experts over that of Patent Owner’s. See Ex. 1133 ¶¶ 111–230 (identifying problems with the approaches proposed by Patent Owner’s experts). For these reasons, we find that a preponderance of the evidence of record better supports a finding that in the 2011–2012 timeframe, it would have been unpredictable to identify which multiple” slip op. at 53

  • Disclosure Requirements (§112) › Enablement (Wands, Amgen full scope)Not enabledUnpatentable

    “an enzyme has folded,” Dr. Naismith states, “there would need to be additional evidence to justify a conclusion that the folded enzyme is sufficiently stable to retain its folded state” and “a POSA would not believe an enzyme had ‘properly folded’ if it did not maintain activity over a meaningful period or if it formed aggregates within a short period.” Id. ¶ 59.” slip op. at 78

  Patent outcomesUS 12,110,520 unpatentable
  § 103 obviousness§ 112 disclosurecites Phillips · KSR · Graham
  Patents in suitUS 12,110,520
• Tesla, Inc. v. Charge Fusion Technologies, LLCAll claims unpatentable
  PTAB · Jul 13, 2026 · IPR2025-00153 · APJ Carl M Defranco · IPR · Final written decision

  Claims 1–30 are unpatentable as obvious under § 103 over the asserted combinations of prior art.

  RulingsFinal written decision

  • Skill levelSkill level petitioner adoptedDecided for petitioner

    “understanding of one of ordinary skill in the art at the time of the invention. Tesla submits that one of ordinary skill in the art would have had at least a bachelor’s degree in electrical or mechanical engineering (or an equivalent field) and at least two years of work experience involving automotive systems, including electric vehicle power management. . . . Additional industry 1 US 2009/0313034 A1, pub. Dec. 17, 2009 (Ex. 1004, “Ferro”). 2 EP 1,920,968 A1, pub. May 14, 2008 (Ex. 1005, “Oyobe”). 3 US 7,124,691 B2, iss. Oct. 24, 2006 (Ex. 1006, “Donnelly”). 4 Steven E. Letendre, The V2G Concept: A New Model for Power? PUBLIC UTILITIES FORTNIGHTLY, Feb. 15, 2002, at 16 (Ex. 1007, “Letendre”). 5 US 5,654,621, iss. Aug. 5, 1997 (Ex. 1078, “Seelig”). 6 US 6,662,083 B1, iss. Sep. 16, 2003 (Ex. 1010, “Knockeart”). experience or technical training may offset less formal education, while advanced degrees or additional formal education may offset lesser levels of industry experience. Pet. 2 (citing Ex. 1003 ¶¶ 14–15). Charge Fusion “takes no position with respect to Petitioner’s proposed level of ordinary skill.” PO Resp. 17. For purposes of our analysis, we apply Tesla’s proposed level of ordinary skill, which we find to be consistent with the problems addressed in the ’987 patent and the prior art. B. Claim Interpretation” slip op. at 6

  • Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)No construction neededOther

    “1. “dynamic attribute of an electric charge provider” In the Petition, Tesla proposes that we construe “dynamic attribute of an electric charge provider,” as recited in every independent claim, to mean “a changing or otherwise fluctuating cost (or price) of electricity for purchase from an electric charge provider.” Pet. 4–5. Charge Fusion responds that Tesla improperly narrows the meaning of this claim limitation. PO Resp. 15 (arguing this claim term “is not just limited to ‘changing or otherwise fluctuating cost (or price)’ as alleged by the Petition” (emphasis added)). Although we consider Tesla’s proposed construction to identify an exemplary “dynamic attribute of an electric charge provider,” we see no need to limit the meaning of this limitation as proposed by Tesla. Indeed, Tesla agrees. See Pet. Reply. 7 (arguing only that this claim limitation “at least includes” such an example). And Charge Fusion does not contend otherwise. See PO Resp 15 (arguing only that this limitation “is not just limited to” cost fluctuations). As such, we see no need to further construe this claim limitation. 2. “determine . . . a charging schedule for the vehicle” Limitation 1[g] recites “determine, based at least on the one or more charging preferences and at least one current value of a dynamic attribute of an electric charge provider, a charging schedule for the vehicle.” Independent claim 8, 15, and 22 recite a materially identical limitation. Tesla submits that this limitation should not be construed as a means-plus- function limitation under 35 U.S.C. § 112(6). See Pet. 5. Charge Fusion agrees that “nothing in the claim invokes [§] 112(6).” PO Resp. 16. As such, we discern no dispute regarding the meaning of this claim limitation.” slip op. at 8

  • Claim Construction › Intrinsic evidence (Phillips canons) › Plain and ordinary meaning to a POSITATerm construed board ownDecided for petitioner

    “Initially, we note that, as claimed, there is no express restriction on the manner in which the “amount” or “charge” is specified or otherwise expressed. Indeed, the Specification uses both “desired charge percent level” and “desired charge range level” as alternative ways for a user to specify an “amount of charge.” Ex. 1001, 14:53–15:8 (emphases added). The Specification defines “desired charge range level” as meaning “a desired distance to travel.” Id. at 15:3–8. Elsewhere, the Specification describes that a user may specify the amount of charge as follows: “the user may indicate a desired charging level (and/or a desired charging level may be automatically calculated) based on a desired distance of travel.” Id. at 19:49–57 (emphasis added). More specifically, annotated Figure 7 of the ’987 patent, reproduced below, demonstrates how a user may select “amount of charge” in terms of a desired mileage range 720 or a percentage level 718. See Pet. Reply 2. As shown in red, annotated Figure 7 illustrates that a user selects “desired charge level 720” on “vehicle charge indicator 714” by moving a slider to a value specified in “miles” (e.g., 110 miles). The Specification, after discussing selecting a desired charge percent level 718, explains: The user may also or alternatively view and/or change the desired charge range level 720. An estimate of how far the vehicle can travel on a given charge amount (which may be a general average and/or may be computed based on a specific itinerary and/or past driving habits) can be determined, for example, and utilized to express the desired charge level in terms of distance capable of being traveled. In such a manner, for example, a user may determine a desired distance to travel (e.g., how far it is from home to work or vice versa) and may set the desired charge range level 720 to match the desired distance. Ex. 1001, 14:65–15:8. Thus, the Specification confirms that “amount of charge” may be expressed in terms of a desired mileage as well as a desired percentage level.” slip op. at 11

  • Obviousness (§103) › Motivation to combine / reasonable expectation of success › HindsightMotivation foundDecided for petitioner

    “We disagree. Charge Fusion’s reliance on Wonderland is misplaced and does not support the proposition for which it is cited. In Wonderland, the district court denied the accused infringer’s motion for summary judgment of invalidity, in part, because genuine issues of material fact existed as to whether there was sufficient motivation to combine the prior art. Wonderland, 988 F. Supp. 2d at 511. As such, the district court’s Wonderland decision does not constitute a final ruling on the motivation to combine issue, and the Federal Circuit’s summary affirmance of the district court’s ruling neither addresses the issue nor reflects how the issue was resolved at trial. See Wonderland NurseryGoods Co. v. Thorley Indus., LLC, 644 F. App’x 1011 (Fed. Cir. 2016). Moreover, contrary to Charge Fusion’s assertion, Tesla correctly notes that although Ferro refers to wireless charging, it provides no implementation details. Ex. 1004 ¶ 36; Ex. 2006, 54:8–55:9. Nonetheless, Ferro does describe manual options for initiating charging, and Tesla’s expert credibly testifies that one of ordinary skill in the art would have been motivated to apply Oyobe’s vehicle sensor to allow a user to initiate Ferro’s charging methods more easily without having to leave the vehicle. See Ex. 1003 ¶¶ 146, 151, 152 (citing Ex. 1004 ¶ 109). Accordingly, we find that Tesla establishes that one of ordinary skill in the art would have been motivated to incorporate Oyobe’s use of a sensor to establish presence of a vehicle near a charging station into Ferro’s system.” slip op. at 17

  Patent outcomesUS 11,631,987 unpatentable
  Claim construction§ 103 obviousnesscites Phillips
  Patents in suitUS 11,631,987
• Tesla, Inc. v. Charge Fusion Technologies, LLCAll claims unpatentable
  PTAB · Jul 13, 2026 · IPR2025-00152 · APJ Carl M Defranco · IPR · Final written decision

  Claims 1–17 are unpatentable as obvious: claims 1–4, 6–9, and 11–14 over Sutardja, Donnelly, and Letendre; claims 5, 10, and 15 with Seelig; claims 16 and 17 with Knockeart.

  RulingsFinal written decision

  • Skill levelSkill level petitioner adoptedDecided for petitioner

    “understanding of one of ordinary skill in the art at the time of the invention. Tesla submits that one of ordinary skill in the art would have had at least a bachelor’s degree in electrical or mechanical engineering (or an equivalent field) and at least two years of work experience involving automotive systems, including electric vehicle power management. . . . Additional industry experience or technical training may offset less formal education, 1 US 2008/0136371 A1, pub. Jun. 12, 2008 (Ex. 1011, “Sutardja”). 2 US 7,124,691 B2, iss. Oct. 24, 2006 (Ex. 1006, “Donnelly”). 3 Steven E. Letendre, The V2G Concept: A New Model for Power? PUBLIC UTILITIES FORTNIGHTLY, Feb. 15, 2002, at 16 (Ex. 1007, “Letendre”). 4 US 5,654,621, iss. Aug. 5, 1997 (Ex. 1078, “Seelig”). 5 US 6,622,083 B1, iss. Sep. 16, 2003 (Ex. 1010, “Knockeart”). while advanced degrees or additional formal education may offset lesser levels of industry experience. Pet. 2–3 (citing Ex. 1003 ¶ 29). Charge Fusion “takes no position with respect to Petitioner’s proposed level of ordinary skill in the art.” PO Resp. 9. For purposes of our analysis, we apply Tesla’s proposed level of ordinary skill, which we find to be consistent with the problems addressed in the ’788 patent and the prior art. B. Claim Interpretation” slip op. at 6

  • Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)No construction neededDecided for patent owner

    “shown in Figure 7 of the ’788 patent. Pet. 4–5. Charge Fusion responds that Tesla’s proposed construction should be rejected because it “wrongly import[s] embodiments from the specification.” PO Resp. 14–16. We discern no dispute over the meaning of “unitary vehicle charge indicator” because, contrary to what Charge Fusion argues, Tesla does not contend that this limitation is “required to be limited to” the bar graph embodiment of Figure 7, only that it “at least includes” that embodiment. Compare Pet. 5, with PO Resp. 14–16. Tesla also argues that the “first” and “second” portions of the unitary vehicle charge indicator—which indicate the charged and uncharged capacities of the battery—recite merely “communicative content,” and thus, are “not entitled to any patentable weight” because they are directed to nonfunctional printed matter. Pet. 5–7 (citing various case law). At the same time, however, Tesla maintains that “[r]egardless, Donnelly teaches a bar graph indicating the amount of charge and uncharged capacity.” Pet. Reply 11–12 (citing Pet. 33–34); see also Hrg. Tr. 74:22–25, 75:9–11. For reasons expressed below, we agree that Tesla persuasively demonstrates that the asserted combination teaches the “unitary vehicle charge indicator element” as claimed and construed by Charge Fusion. Accordingly, we need not decide the printed matter issue.” slip op. at 8

  • Claim Construction › Intrinsic evidence (Phillips canons) › Plain and ordinary meaning to a POSITATerm construed petitioner constructionDecided for petitioner

    “Initially, we note that, as claimed, there is no express restriction on the manner in which the “amount” or “charge” is specified or otherwise expressed. Indeed, the Specification uses both “desired charge percent level” and “desired charge range level” as alternative ways for a user to specify an “amount of charge.” Ex. 1001, 14:63–15:18 (emphases added). In particular, the Specification defines “desired charge range level” as meaning “a desired distance to travel.” Id. at 15:8–18. Elsewhere, the Specification describes that a user may specify the amount of charge as follows: “the user may indicate a desired charging level (and/or a desired charging level may be automatically calculated) based on a desired distance of travel.” Id. at 19:59–67 (emphasis added).” slip op. at 9

  • Obviousness (§103) › Graham factors (scope of art, differences, level of skill)UnpatentableUnpatentable

    “full charge” for the battery, and thus, Tesla fails to explain how the combination of Sutardja with Donnelly’s battery bar graph image “would allow a user to select a specific amount of charge or how this would result in a unitary vehicle charge indicator,” as claimed. PO Resp. 30. According to Charge Fusion, “[l]imiting the single option of ‘full charge’ as described in Sutardja would defeat the purpose of implementing a slider” as taught by Donnelly. Id. (citing Ex. 2008 ¶ 72). We disagree. Charge Fusion’s argument rests on the mistaken premise that Sutardja only contemplates selecting a full amount of charge for the battery and not an amount below a full charge, i.e., a partial charge. But that is not what Sutardja says. More accurately, Sutardja teaches that the user specifies the amount of charge—"The user interface module 108 may comprise a key pad, a display, a microphone, and/or a speaker (all not shown). A user of the vehicle 102-1 may use the user interface module 108 to set charging parameters for charging the battery 14.” Ex. 1011 ¶ 243. Elsewhere, Sutardja teaches that the user may set a “predetermined level” of charge— The charge monitoring module 150 may inform the control module 112 when the battery 14 is charged to a predetermined level (e.g., full charge) that may be indicated in the charging parameters. Subsequently, the charge monitoring module 150 may stop charging the battery 14 by deactivating the converter 156 and the charging module 152. The power meter 24 may measure the amount of power received from the utility company 23 during the charging operation. Id. ¶ 270 (emphases added). Although that passage indicates that a “full charge” is an example of a “predetermined level” of charge, nowhere does it exclude the selection of a lesser amount. Indeed, the passage contemplates the ability to “stop charging the battery,” which indicates that selection of the predetermined level may be less than a full charge. Id. Thus, we are not persuaded by Charge Fusion’s argument to the contrary. Rather, in our view, Tesla demonstrates by a preponderance of the evidence that the Sutardja-Donnelly combination teaches a “unitary vehicle charge indicator” that includes at least “first” and “second” portions and that one of ordinary skill in the art would have had reason to successfully combine their respective teachings in a manner that allows a user to predetermine, i.e., specify, an amount of charge. slip op. at 17

  Patent outcomesUS 11,990,788 unpatentable
  Claim construction§ 103 obviousnesscites Phillips
  Patents in suitUS 11,990,788
• GD Energy Products, LLC v. Kerr Machine CompanyAll claims unpatentable
  PTAB · Jun 29, 2026 · PGR2025-00031 · APJ Ryan H Flax · PGR · Final written decision

  Claims 1–14 are unpatentable as obvious under each of four asserted grounds: Kerr; Aplex and Stanton; Blume, Stanton, and Wilkinson; and the sale of the Kerr Pump.

  RulingsFinal written decision

  • Skill levelSkill level petitioner adoptedDecided for petitioner

    “The person of ordinary skill in the art would have a minimum of a bachelor’s degree in mechanical or petrochemical engineering, or a comparable engineering discipline, and a minimum of 3-5 years of work experience in the design and/or manufacturing of reciprocating pumps and valves, including fluid ends and/or comparable high pressure fluid components, for industrial applications, including for use in the oil and gas industry. See, e.g., EX1003, ¶32.” slip op. at 12

  • Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)No construction neededOther

    “[W]e need only construe terms ‘that are in controversy, and only to the extent necessary to resolve the controversy.’” Nidec Motor Corp. v. Zhongshan Broad Ocean Motor Co., 868 F.3d 1013, 1017 (Fed. Cir. 2017) (quoting Vivid Techs., Inc. v. Am. Sci. & Eng’g, Inc., 200 F.3d 795, 803 (Fed. Cir. 1999)). We decline to expressly construe any claim language. slip op. at 12

  • Obviousness (§103) › Motivation to combine / reasonable expectation of successMotivation foundReasonable expectation foundDecided for petitioner

    “Regarding the combining of Aplex and Stanton, Petitioner asserts that the ordinarily skilled artisan would have understood that providing a packing/stuffing arrangement, as taught by Stanton, within a fluid end housing, as taught by Aplex, would improve pressure and fluid isolation compared with an arrangement where the packing was bolted to the outside of the fluid end as in Aplex unmodified. Pet. 66 (citing Ex. 1003 ¶¶ 189, 236). Patent Owner does not dispute this rationale. We find this to be a reason, with rationale underpinning, why the person of ordinary skill in the art would have combined these references with a reasonable expectation of success.” slip op. at 29

  • Adverse judgmentOther

    “The record indicates that Patent Owner has statutorily disclaimed claim 15 as of April 28, 2025. Ex. 2206.” slip op. at 8

  Patent outcomesUS 12,152,582 unpatentable
  Claim construction§ 103 obviousnesscites KSR · Graham
  Patents in suitUS 12,152,582
• Merck Sharp & Dohme LLC v. Halozyme, Inc.All claims unpatentable
  PTAB · Jun 24, 2026 · PGR2025-00009 · APJ Susan L C Mitchell · PGR · Final written decision

  Claims 1, 2, 6–14, and 16–29 are unpatentable based on written description, enablement, and obviousness grounds.

  RulingsFinal written decision

  • Director reviewDirector review, deniedDenied

    “Following institution, Patent Owner filed a Director Review Request (Paper 33), and Petitioner filed an Authorized Response (Paper 37), and the then-Acting Director issued a denial of the Director Review Request. Paper 40.” slip op. at 3

  • Additional discoveryAdditional discovery, deniedDenied

    “(Paper 46, “PO Resp.”), Petitioner filed a Reply to Patent Owner’s Response (Paper 71, “Pet. Reply”), and Patent Owner filed a Sur-reply (Paper 84, “PO Sur-reply”). Patent Owner filed a motion for additional discovery (Paper 62), Petitioner opposed the Motion for Discovery (Paper 63), and the Board denied the Motion for Discovery (Paper 77).” slip op. at 3

  • Skill levelSkill level petitioner adoptedDecided for petitioner

    “II. ANALYSIS A. Level of Ordinary Skill in the Art We consider the grounds of unpatentability in view of the” slip op. at 8

  • Disclosure Requirements (§112) › Written description (Ariad)Written description inadequateUnpatentable

    “description itself. To the extent the experts disagree on this point, we credit the testimony of Petitioner’s experts over that of Patent Owner’s. For these reasons, we find that a preponderance of the evidence of record better supports a finding that in the 2011–2012 timeframe, it would have been unpredictable to identify which multiple mutants retained hyaluronidase activity, even with the single substitution data provided by the ’035 patent.” slip op. at 53

  Patent outcomesUS 12,123,035 unpatentable
  § 103 obviousness§ 112 disclosurecites Phillips · KSR · Graham
  Patents in suitUS 12,123,035
• Merck Sharp & Dohme LLC v. Halozyme, Inc.All claims unpatentable
  PTAB · Jun 8, 2026 · PGR2025-00004 · APJ Susan L C Mitchell · PGR · Final written decision

  Claims 1–4, 7–19, and 22 are unpatentable under § 112(a) for lack of written description and enablement, and under § 103 as obvious.

  RulingsFinal written decision

  • Skill levelSkill level petitioner adoptedDecided for petitioner

    “II. ANALYSIS A. Level of Ordinary Skill in the Art We consider the grounds of unpatentability in view of the” slip op. at 8

  • Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)No construction neededDecided for patent owner

    “1. Petitioner’s Position Petitioner asserts that the “terms used in the claims are either” slip op. at 12

  • Disclosure Requirements (§112) › Written description (Ariad)Written description inadequateUnpatentable

    “7. Analysis We find the preponderance of the evidence supports a finding that the” slip op. at 59

  • Disclosure Requirements (§112) › Enablement (Wands, Amgen full scope)Not enabledUnpatentable

    “6. Analysis Petitioner has the burden to identify how the specification allegedly” slip op. at 70

  Patent outcomesUS 12,018,298 unpatentable
  Claim construction§ 103 obviousness§ 112 disclosurecites Phillips · KSR · Graham
  Patents in suitUS 12,018,298
• Trove Brands, LLC v. Camelbak Products, LLCSome claims unpatentable
  PTAB · Jun 2, 2026 · IPR2025-00140 · APJ Carl M Defranco · IPR · Final written decision

  Claims 1–6 are unpatentable as obvious; claims 7–18 were not shown unpatentable because Ribarits does not disclose a mouthpiece disposed on the pivotal mount.

  RulingsFinal written decision

  • Skill levelSkill level petitioner adoptedDecided for petitioner

    “Trove contends that a person of ordinary skill in the art “would have had an undergraduate degree in mechanical engineering or equivalent coursework, and a year or more of experience in designing, prototyping, and/or manufacturing fluid containers or similar products” and that “[m]ore work experience may substitute for a lower level of education, and vice versa.” Pet. 15 (citing Ex. 1002 ¶ 25). While CamelBak offers “a similar, though slightly different level,” it nonetheless “discerns no material difference between the definitions provided by the parties for purposes of the Board’s decision in this proceeding.” PO Resp. 27. That being the case, we adopt Trove’s proposed definition of the level of skill in the art, as it is 2 JP 2002-211613A, published July 31, 2002 (Ex. 1004, “Nakajima”). 3 WO 2004/063042 A2, published July 29, 2004 (Ex. 1006, “Ribarits”). 4 US 4,485,963, issued Dec. 4, 1984 (Ex. 1007, “Panicci”). 5 US 6,523,711 B1, issued Feb. 25, 2003 (Ex. 1008, “Hughes”). reasonable and consistent with what is reflected in the asserted prior art and the specification of the ’250 patent. B. Claim Construction” slip op. at 7

  • Claim Construction › Intrinsic evidence (Phillips canons) › Plain and ordinary meaning to a POSITATerm construed patent owner constructionDecided for patent owner

    “We will not bite. CamelBak’s original assertion—that the plain and ordinary meaning of the constituent parts of “mouth” and “piece” is “a piece (or part) that goes in the mouth”—underscores the fallacy of CamelBak’s additional physical contact requirement. PO Resp. 28 (emphasis added). Indeed, in support of that earlier assertion, CamelBak pointed to the very dictionary definition that we relied on at institution in construing “mouthpiece” as a part that either “goes in the mouth or to which the mouth is applied.” See id. at 31 (citing Ex. 2005 (emphasis added)). Even the original testimony of CamelBak’s own expert confirms that one skilled in the art “would understand that the term ‘mouthpiece’ is commonly known in the art as a part designed for a user’s mouth,” without any requirement for physical contact with the mouth. Ex. 2016 ¶ 58 (citing Ex. 2005) (emphasis added)). And nothing in the Specification limits that common understanding. Although, indisputably, the Specification contemplates an embodiment where the user physically contacts the mouthpiece with their teeth (i.e., a bite-actuated mouthpiece), it also contemplates an embodiment where the user simply inserts the bottle in their mouth and commences fluid flow by squeezing it. See Ex. 1001, 10:9–13. That disclosure supports a meaning of “mouthpiece” that simply requires placement in the opening of the user’s mouth without necessarily incurring physical contact with some portion of the mouth, such as the teeth, tongue, or lips. Indeed, had CamelBak wished to premise the meaning of “mouthpiece” on some sort of physical contact with the mouth, it knew how to do so. For instance, the independent claims of CamelBak’s earlier ’255 patent, which is the subject of the related 1137 IPR, are limited in just such a manner, as they recite “wherein the resilient mouthpiece is adapted to resiliently compress responsive to compressive forces applied to the resilient mouthpiece by a user’s teeth.” Ex. 2023, at 20–25 (emphasis added). Thus, we reject CamelBak’s attempt to narrow our construction of “mouthpiece” to something other than “a part (as of an instrument) that goes in the mouth or to which the mouth is applied.” Neither the intrinsic nor extrinsic evidence supports the narrower construction proposed by CamelBak.” slip op. at 11

  • Expert testimonyPetitioner expert discountedDecided for patent owner

    “In reply, Trove argues that CamelBak’s “novel” construction that the mouthpiece moves with rotational motion about that same axis of rotation defined by the two joint as the pivotal mount and in the same direction as the pivotal mount “are inconsistent with the claim language’s plain and ordinary meaning and find no support in the intrinsic and extrinsic record.” See Pet. Reply 16. But, because we find that, when properly construed, the claimed “pivotal movement with the pivotal mount” about “two joints that define a pivotal axis” requires that the mouthpiece rotate about the same axis and in the same direction as the pivotal mount, we reject Trove’s argument as unavailing. And, although we agree with Trove that Nakajima’s mouthpiece engages in counter-clockwise rotation about a “Second Pivot Axis” when Nakajima’s lid 4 is opened (id. at 20–22), that rotation is about a different axis—one defined by Nakajima’s protrusions 24 rather than the claimed “pivotal axis” defined by Nakajima’s hinge shafts 19—and in a different manner—an upward and counterclockwise path rather than the claimed “pivotal movement with the pivotal mount” defined by Nakajima’s lid 4. Finally, in an alternative theory, Trove and its expert use “image- manipulation tools” in an attempt to show that Nakajima’s mouthpiece engages in some initial “clockwise-rotation” with Nakajima’s lid as it is opened. See Pet. Reply 18–24. We reject that theory as entirely conjectural and unsupported by the evidence.” slip op. at 39

  • Obviousness (§103) › Motivation to combine / reasonable expectation of successNot shown unpatentableNot shown unpatentable

    “We disagree. As discussed above, the proper construction of “for pivotal movement with the pivotal mount” requires that the mouthpiece mirror the rotational movement of the pivotal mount, i.e., rotate about the same axis as the pivotal mount and in the same direction as the pivotal mount. See supra § II.B.3. But Nakajima’s mouthpiece does neither, and, thus, does not exhibit the claimed “pivotal movement with the pivotal mount” about “two joints that define a pivotal axis for . . . the pivotal mount axis,” as properly construed.” slip op. at 36

  Patent outcomesUS 11,851,250 mixed
  Claim construction§ 103 obviousness
  Patents in suitUS 11,851,250

Holdings, summaries, rulings, issues, outcomes, winners and claim constructions shown for a decision were generated by a large language model reading the opinion. They are a guide to the decision, not the decision. Confirm every one against the court's own text before relying on it. Outcomes read from the patent owner’s side. Party names are extracted from the decision and are missing on about 900 short Director denials and scans, which carry the trial number instead.